Although preclinical studies have suggested that EGFR-driven NSCLC inhibits antitumor immunity through activation of the PD-1/PD-L1 pathway in an intrinsic manner, epidemiological studies have suggested that EGFR-mutant NSCLC is more likely to exhibit decreased PD-L1 expression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.